Antiplatelet agents inhibit platelet. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy9

Blood Platelets Megakaryocytes Platelet-Rich Plasma Cytoplasmic Granules Leukocytes Endothelium, Vascular Cell Membrane Cells, Cultured Melena

Organisms6

Rabbits Dogs Goniothalamus Magnolia Papio Mice, Inbred C57BL

Diseases50

Thrombosis Hemorrhage Acute Coronary Syndrome Stroke Coronary Thrombosis Thromboembolism Postoperative Hemorrhage Thrombocytopenia Myocardial Infarction Recurrence Intracranial Hemorrhages Cerebrovascular Disorders Ischemic Attack, Transient Cerebral Hemorrhage Coronary Artery Disease Brain Ischemia Peripheral Vascular Diseases Purpura, Thrombocytopenic Cardiovascular Diseases Atrial Fibrillation Coronary Disease Myocardial Ischemia Thrombocytosis Postoperative Complications Purpura, Thrombocytopenic, Idiopathic Platelet Storage Pool Deficiency Thrombasthenia Carotid Artery Thrombosis Intracranial Thrombosis Blood Coagulation Disorders Bernard-Soulier Syndrome Embolism Graft Occlusion, Vascular Hematoma Thrombocythemia, Essential Blood Loss, Surgical Embolism, Cholesterol Coronary Restenosis Angina, Unstable Gray Platelet Syndrome Intracranial Embolism von Willebrand Diseases Gastrointestinal Hemorrhage Trigger Finger Disorder Purpura, Thrombotic Thrombocytopenic Coronary Stenosis Afibrinogenemia Acute Disease Melena Hemorrhagic Disorders

Chemicals and Drugs121

Platelet Aggregation Inhibitors Aspirin Ticlopidine Thienopyridines Platelet Glycoprotein GPIIb-IIIa Complex Anticoagulants Receptors, Purinergic P2Y12 Dipyridamole Purinergic P2Y Receptor Antagonists Thiophenes Platelet Membrane Glycoproteins Fibrinolytic Agents Adenosine Diphosphate Dilazep Platelet Factor 4 Thrombin Warfarin Phosphodiesterase 3 Inhibitors Purinergic P2 Receptor Antagonists Platelet Activating Factor Platelet Glycoprotein GPIb-IX Complex Immunoglobulin Fab Fragments Tetrazoles Piperazines Cardiovascular Agents Antigens, Human Platelet Collagen Heparin P-Selectin Receptor, PAR-1 Fibrinogen Vitamin K Phenprocoumon Adenosine Pyridines Thromboxane A2 von Willebrand Factor Antibodies, Monoclonal Hydroxymethylglutaryl-CoA Reductase Inhibitors Thromboxanes Platelet Membrane Glycoprotein IIb Angiotensin-Converting Enzyme Inhibitors Platelet Factor 3 Adrenergic beta-Antagonists Sulfinpyrazone Serotonin Epoprostenol Thromboxane B2 Ristocetin Receptors, Thromboxane Hirudins Receptors, Thrombin Crotalid Venoms Arachidonic Acid Thrombopoietin Blood Proteins Calcium Blood Coagulation Factors Thromboxane-A Synthase Epinephrine Prostaglandin Endoperoxides, Synthetic Antithrombins Fibrin Phenazopyridine Receptors, Thromboxane A2, Prostaglandin H2 Acenocoumarol Cyclooxygenase Inhibitors Dual Specificity Phosphatase 2 Aryl Hydrocarbon Hydroxylases Receptors, Purinergic P2Y1 Apyrase Receptors, Purinergic P2 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid Isoantibodies Indium Fibrinopeptide A Receptors, Collagen Arachidonic Acids Oligopeptides 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid Thromboplastin Cyclooxygenase 1 Antibodies Quinidine Thrombospondins Recombinant Proteins Tablets, Enteric-Coated Oxyquinoline Heparin, Low-Molecular-Weight Peptide Fragments Factor Xa Calcimycin Sirolimus Microfilament Proteins Proton Pump Inhibitors Drug Combinations Autoantibodies Membrane Proteins Edetic Acid Nitroso Compounds 6-Ketoprostaglandin F1 alpha Adenosine Monophosphate Tyrosine Integrin alpha2 Nitric Oxide Anti-Inflammatory Agents, Non-Steroidal Cyclic AMP Peptides S-Nitrosoglutathione Isoindoles Adenosine Triphosphate Salicylates Receptors, Thrombopoietin Cell Adhesion Molecules Antifibrinolytic Agents Antithrombin III Cyclic GMP Lactones Integrin alpha2beta1 Enoxaparin Glycoproteins

Analytical, Diagnostic and Therapeutic Techniques and Equipment45

Platelet Function Tests Platelet Count Bleeding Time Drug Therapy, Combination Platelet Transfusion Treatment Outcome Stents Risk Factors Angioplasty, Balloon, Coronary Perioperative Care Administration, Oral Prospective Studies Risk Assessment Follow-Up Studies Retrospective Studies Thrombolytic Therapy Randomized Controlled Trials as Topic Clinical Trials as Topic Double-Blind Method Registries Incidence Drug-Eluting Stents Thrombelastography Blood Coagulation Tests Percutaneous Coronary Intervention Flow Cytometry Hemorheology Blood Preservation Blood Cell Count Plateletpheresis Partial Thromboplastin Time Drug Administration Schedule Coronary Angiography Blood Transfusion International Normalized Ratio Premedication Prosthesis Design Prothrombin Time Mean Platelet Volume Splenectomy Withholding Treatment Whole Blood Coagulation Time Drug Monitoring Cross-Over Studies Hematocrit

Phenomena and Processes26

Platelet Aggregation Platelet Adhesiveness Platelet Count Bleeding Time Platelet Activation Time Factors Dose-Response Relationship, Drug Drug Resistance Blood Coagulation Hemostasis Thrombopoiesis Hemorheology Drug Interactions Kinetics Blood Cell Count Partial Thromboplastin Time Fibrinolysis Prothrombin Time Mean Platelet Volume Phosphorylation Protein Binding Cell Adhesion Amino Acid Sequence Whole Blood Coagulation Time Signal Transduction Hematocrit

Information Science4

Registries Incidence Amino Acid Sequence Molecular Sequence Data

Health Care17

Treatment Outcome Secondary Prevention Risk Factors Perioperative Care Prospective Studies Risk Assessment Follow-Up Studies Retrospective Studies Randomized Controlled Trials as Topic Clinical Trials as Topic Double-Blind Method Practice Guidelines as Topic Registries Incidence Point-of-Care Systems Withholding Treatment Cross-Over Studies

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Information Science Health Care

Platelet Aggregation Inhibitors Platelet Aggregation Blood Platelets Aspirin Ticlopidine Platelet Function Tests Platelet Adhesiveness Thrombosis Platelet Count Bleeding Time Thienopyridines Platelet Glycoprotein GPIIb-IIIa Complex Hemorrhage Anticoagulants Receptors, Purinergic P2Y12 Dipyridamole Purinergic P2Y Receptor Antagonists Thiophenes Platelet Membrane Glycoproteins Drug Therapy, Combination Fibrinolytic Agents Platelet Activation Acute Coronary Syndrome Adenosine Diphosphate Platelet Transfusion Dilazep Platelet Factor 4 Stroke Thrombin Warfarin Coronary Thrombosis Treatment Outcome Thromboembolism Phosphodiesterase 3 Inhibitors Secondary Prevention Purinergic P2 Receptor Antagonists Platelet Activating Factor Platelet Glycoprotein GPIb-IX Complex Immunoglobulin Fab Fragments Stents Risk Factors Postoperative Hemorrhage Tetrazoles Angioplasty, Balloon, Coronary Piperazines Thrombocytopenia Perioperative Care Cardiovascular Agents Antigens, Human Platelet Myocardial Infarction Collagen Time Factors Recurrence Heparin Intracranial Hemorrhages Cerebrovascular Disorders Ischemic Attack, Transient Administration, Oral P-Selectin Receptor, PAR-1 Fibrinogen Vitamin K Megakaryocytes Cerebral Hemorrhage Prospective Studies Coronary Artery Disease Risk Assessment Phenprocoumon Adenosine Brain Ischemia Dose-Response Relationship, Drug Follow-Up Studies Drug Resistance Peripheral Vascular Diseases Pyridines Retrospective Studies Thromboxane A2 von Willebrand Factor Purpura, Thrombocytopenic Thrombolytic Therapy Cardiovascular Diseases Randomized Controlled Trials as Topic Antibodies, Monoclonal Blood Coagulation Clinical Trials as Topic Atrial Fibrillation Double-Blind Method Hydroxymethylglutaryl-CoA Reductase Inhibitors Coronary Disease Hemostasis Thromboxanes Practice Guidelines as Topic Platelet Membrane Glycoprotein IIb Angiotensin-Converting Enzyme Inhibitors Registries Platelet Factor 3 Incidence Adrenergic beta-Antagonists Sulfinpyrazone Drug-Eluting Stents

No FAQ available that match "antiplatelet agents inhibit platelet"